肥満 と 心房 動: 仕組み から 治療 へ
Jenelle K Dziano1, Jonathan P Ariyaratnam2, Melissa E Middeldorp3
1Centre for Heart Rhythm Disorders, The University of Adelaide, Royal Adelaide Hospital and South Australian Health & Medical Research Institute, Adelaide, SA, Australia. Electronic address: https://x.com/JenelleDziano.
Heart, lung & circulation
|September 4, 2025
まとめ
肥満は様々な生物学的メカニズムによって心房細動 (AF) の発生リスクを大幅に増加させます. 体重減少戦略は AFの管理と 増加する流行の予防に不可欠です
科学分野:
- 心臓病科
- 代謝障害
- 公衆衛生
背景:
- 世界の肥満率は上昇し 2050年までに38億人が 肥満に罹ると予測されています
- 心房細動 (AF) の発生率と流行率は 肥満の流行に並行して増加しています
- 肥満は左心房の改造,心臓の脂肪,炎症,併発症などのメカニズムで AFに関連しています.
研究 の 目的:
- 肥満が心房細動 (AF) の重要な危険因子と関連している証拠をレビューする.
- AFのケアにおける肥満管理の現在の治療法と新たな治療法を議論する.
- 地域社会における AF の増加を防ぐための戦略を探求する.
主な方法:
- 既存の科学的証拠の文献レビュー
- 肥満が AF の発達に影響する経路の分析
- AFにおける併発性疾患 (高血圧,糖尿病,睡眠時無呼吸症) の役割の検討
- AF再発に対する治療的介入としての体重減少の評価
主要な成果:
- 肥満は,左心房の改造,心臓の脂肪組織,心臓の負荷の変化,炎症,RAASの活性化によってAFに寄与する.
- 体重減少は,症状のAF再発を減らすための重要な要因として確立されています.
- 肥満の薬学的な治療は AF患者のケアを 改善するための新しい道を開きます
結論:
- 肥満は心房細動 (AF) の主要な変化可能な危険因子です.
- 肥満とその併発症の統合管理は AFの予防と治療に不可欠です.
- 肥満に対する新薬療法は AFの改善に 期待を寄せています
関連する概念動画
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Obesity
609
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
609
Coronary Artery Disease I: Introduction
54
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
54
Dysrhythmias VI: Management of Dysrhythmias
106
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
106
Aortic Regurgitation III: Medical Management
39
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
39
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27


